Alternative Medications for Temazepam Non-Response

First-Line Alternatives Based on Insomnia Pattern

The American Academy of Sleep Medicine recommends eszopiclone 2-3 mg at bedtime for both sleep onset and sleep maintenance insomnia, with intermediate duration of action and no short-term usage restriction 1, 2
The American Academy of Sleep Medicine recommends zolpidem 10 mg at bedtime for both sleep onset and maintenance insomnia, with demonstrated improvements in total sleep time of approximately 30 minutes and wake after sleep onset reductions of 25 minutes 1, 2, 4
The American Academy of Sleep Medicine recommends low-dose doxepin 3-6 mg at bedtime specifically for sleep maintenance insomnia, with efficacy in increasing deep sleep duration and minimal anticholinergic effects at these doses 1, 2
The American Academy of Sleep Medicine recommends suvorexant 10-20 mg as an orexin receptor antagonist for sleep maintenance insomnia, representing a different mechanism of action than benzodiazepine receptor agonists 1, 2

The American Academy of Sleep Medicine does not recommend switching to zaleplon, triazolam, or ramelteon if the patient has sleep maintenance problems, as these are too short-acting and only address sleep onset 3
The American Academy of Sleep Medicine does not recommend trazodone for insomnia treatment due to limited evidence supporting its efficacy 1, 2
The American Academy of Sleep Medicine advises against using diphenhydramine, melatonin, L-tryptophan, valerian, and tiagabine as these are specifically not recommended by guideline evidence 1, 2

For patients with predominantly difficulty falling asleep, the American Academy of Sleep Medicine suggests considering eszopiclone, zolpidem, or even triazolam 0.25 mg 1, 2
For patients with predominantly early morning awakening or frequent nighttime awakenings, the American Academy of Sleep Medicine recommends prioritizing doxepin 3-6 mg or suvorexant 1, 3
For patients with both onset and maintenance problems, the American Academy of Sleep Medicine prefers eszopiclone or zolpidem 1, 2

The American Academy of Sleep Medicine notes that all benzodiazepine receptor agonists (eszopiclone, zolpidem) carry FDA warnings regarding complex sleep behaviors (sleep-walking, sleep-driving), daytime memory impairment, and potential association with dementia in observational studies 3
The American Academy of Sleep Medicine warns that abrupt discontinuation of benzodiazepines can produce withdrawal symptoms including rebound insomnia; taper gradually if switching from temazepam 3
The American Academy of Sleep Medicine rates all pharmacologic recommendations as "WEAK" according to GRADE methodology, indicating that cognitive behavioral therapy for insomnia (CBT-I) should be considered first-line treatment before or alongside pharmacotherapy 3

The American Academy of Sleep Medicine advises against simply increasing temazepam dose beyond 30 mg as this is the maximum studied dose and higher doses increase adverse effects without proven additional benefit 6, 3
The American Academy of Sleep Medicine recommends avoiding switching to another benzodiazepine without considering non-benzodiazepine alternatives first, as cross-tolerance may limit benefit 1, 2
The American Academy of Sleep Medicine advises against prescribing trazodone despite its common off-label use, as it lacks guideline support for insomnia 1, 2
The American Academy of Sleep Medicine recommends avoiding antipsychotics (quetiapine, olanzapine) for primary insomnia without psychiatric comorbidity, as these are not recommended and carry significant metabolic risks 7